Venclexta/Gazyva combo meets PFS endpoint in Phase III for first-line CLL

Genentech Inc. and AbbVie Inc. (NYSE:ABBV) said first-line treatment with Venclexta venetoclax plus Gazyva obinutuzumab met the primary endpoint of improving investigator-assessed progression-free survival (PFS) compared with Gazyva plus chlorambucil in the Phase III CLL14 trial to treat chronic lymphocytic leukemia (CLL). The open-label, international trial enrolled 445 previously untreated CLL patients with coexisting medical conditions.

The partners said the data will be presented at a medical meeting and submitted to worldwide regulatory authorities...